Asthma
Conditions
Keywords
bioavailability, Fluticasone Furoate, pharmacokinetics, dose proportionality
Brief summary
The purpose of this study is to demonstrate dose proportionality of the FF (50 microgram (mcg), 100 mcg or 200 mcg), when administered as a single and repeat dose from the NDPI containing FF formulated with lactose. In addition, the aim of this study is to determine the absolute bioavailability of the FF single strip product using the high strength product administered as a single dose with multiple inhalations and using 250 mcg intravenous (IV) FF. This is a, part-randomized, open-label, 4 way crossover study (4 periods) in healthy adult subjects. During each period, subjects will receive FF in the morning and serial pharmacokinetic (PK) sampling (for up to 10 days for the inhaled treatment and up to 3 days for the IV treatment) and safety assessments will be performed. Each period will be separated by a washout period of at least 7 days and a follow-up telephone call will occur 7 -14 days after the last dose of study drug. The total duration of the study will be approximately 13-14 weeks for each subject.
Interventions
DRUGFF, 50 mcg
Novel dry powder inhaler
DRUGFF, 100 mcg
Novel dry powder inhaler
DRUGFF, 200 mcg
Novel dry powder inhaler
DRUGFF, 250 mcg
Intravenous
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female subjects between 18 and 65 years of age and body mass index (BMI) within the range 18.5 to 29.0 kilogram/meter squared. * Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and bilirubin \< or =1.5x upper limit of normal (ULN). * Female subjects of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy during the study. * Average QT duration corrected for heart rate by Fridericia's formula (QTcF) \<450 millisecond. * Forced Expiratory Volume in 1 Second (FEV1) \> or = 85% predicted at screening. * Current non-smokers * Able to satisfactorily use the NDPI.
Exclusion criteria
* Subjects must not have a systolic blood pressure above 145 milimeter(mm) of mercury(Hg) or a diastolic pressure above 85 mmHg at the screening visit. * History of breathing problems in adult life confirmed by normal lung function parameters (≥85% predicted). * Donation of more than 500 mL blood within a 56 day period. * Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit. * Current or chronic history of liver disease, or known hepatic or biliary abnormalities. * The subject treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness. * The subject has a positive: drug/alcohol, Hepatitis, HIV screen. * Abuse of alcohol. * Subject having positive cotinine and urine alcohol test. * Participated in \>3 clinical trials in the previous 10 months (if male), or \>2 clinical trials in the previous 10 months (if female), or the subject has participated in a study (including follow up) within 60 days prior to the first dosing day in the current study. * Exposure to more than four new chemical entities within 12 months prior to the first dosing day. * Taken systemic, oral or depot corticosteroids less than 12 weeks or inhaled, intranasal or topical steroids less than 4 weeks before the screening visit. * Use of prescription or non-prescription drugs. * History of severe milk protein allergy, sensitivity to any of the study medications, including immediate or delayed hypersensitivity to any intranasal, inhaled or systemic corticosteroid therapy. * Pregnant or lactating females. * Unwillingness or inability to follow the procedures outlined in the protocol. * Subject is mentally or legally incapacitated.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FF pharmacokinetics; parameters: (AUC(0-infinity)) , (AUC(0-24)) and (Cmax) | 54 days | FF pharmacokinetics; area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC (0-infinity)), area under the concentration-time curve from zero (pre-dose) to 24 h (AUC (0-24)) and maximum observed concentration (Cmax). Blood samples for PK analysis of FF will be collected and analysis will be performed. Concentrations of FF will be determined in plasma samples using the currently approved analytical methodology. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma FF PK parameters: V and CL for IV treatment | 3 days (Study Day 52 to Study Day 54) | Following plasma FF PK parameters will be evaluated: volume of distribution (V) and plasma clearance (CL) for intravenous administration Blood samples for PK analysis of FF will be collected and analysis will be performed. Concentrations of FF will be determined in plasma samples using the currently approved analytical methodology. |
| Plasma FF PK parameters: t1/2, tmax, MRT for all treatments | 54 days | Following plasma FF PK parameters will be evaluated: terminal phase half life (t1/2), time of occurrence of Cmax (tmax), mean residence time (MRT) for all treatments Blood samples for PK analysis of FF will be collected and analysis will be performed. Concentrations of FF will be determined in plasma samples using the currently approved analytical methodology. |
| Mean absorption time (MAT) for inhaled treatments | 44 days | Blood samples for PK analysis of FF will be collected and analysis will be performed. Concentrations of FF will be determined in plasma samples using the currently approved analytical methodology. |
| Safety of FF | 68 days | To assess the safety and tolerability of FF administered as single and repeat dose adverse events will be studied. |
Countries
Netherlands
Outcome results
None listed